Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice

Abstract

The objective of the study was to analyse the treatment of high blood pressure (BP) and hypercholesterolaemia, as well as the effect of individual or combined antihypertensive-hypocholesterolaemic therapy on BP control and on circulating cholesterol. A retrospective study was performed using clinical data recorded in the general practitioner's database. The sample included all patients, aged >/=18 years, with BP reading or low-density lipoprotein (LDL) cholesterol measurement recorded between January 2003 and December 2004. BP and LDL cholesterol targets were defined using cutoffs based on the guidelines of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7) and the National Cholesterol Education Program (NCEP/ATPIII). The study included 4764 patients (mean age 67.6±11.8 years, 43.5% males). Target BP was achieved in a higher number of patients under combined antihypertensive-hypocholesterolaemic therapy than in those treated only with antihypertensives: 57.0 vs 50.0% in patients with history of cardio/cerebrovascular (CV) hospitalization, 27.0 vs 16.9% in patients with diabetes or chronic renal insufficiency (CRI) and 59.7 vs 49.1% in patients with no CV hospitalization nor diabetes and nor CRI. The LDL cholesterol target was achieved in 61.3% of the subjects: it was independent on the therapy (individual or combined), but related to the degree of cardiovascular risk. Analysing the data contained in the general medicine database made it possible to evaluate the treatment of high BP and hypercholesterolaemia in relation to cardiovascular risk in clinical practice and to establish the need to pay greater attention to achieving the objective set by guidelines.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lander ES, Schork NJ . Genetic dissection of complex trait. Science 1994; 265: 2037–2048.

    Article  CAS  Google Scholar 

  2. Ward R . Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn, Raven Press: New York, 1995, pp. 67–88.

    Google Scholar 

  3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003; 289: 2560–2572.

  4. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.

    Article  Google Scholar 

  5. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee. J Hypertens 2003; 21: 1011–1053.

  6. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A . Blood pressure control in the hypertensive population. Lancet 1997; 349: 454–457.

    Article  CAS  Google Scholar 

  7. Primatesta P, Poulter NR . Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens 2006; 24: 1187–1192.

    Article  CAS  Google Scholar 

  8. Muntner P, DeSalvo KB, Wildman RP, Raggi P, He J, Whelton PK . Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol 2006; 163: 913–920.

    Article  Google Scholar 

  9. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, et al., InterASIA Collaborative Group. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation 2004; 110: 405–411.

    Article  CAS  Google Scholar 

  10. Ford ES, Mokdad AH, Giles WH, Mensah GA . Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185–2189.

    Article  Google Scholar 

  11. Primatesta P, Poulter NR . Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxford) 2006; 64: 292–298.

    Article  Google Scholar 

  12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

  13. Jiang J, Roman RJ . Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: 968–974.

    Article  CAS  Google Scholar 

  14. Vogel RA, Corretti MC, Plotnick GD . Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77: 37–40.

    Article  CAS  Google Scholar 

  15. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519–2524.

    Article  CAS  Google Scholar 

  16. Goode GK, Miller JP, Heagerty AM . Hyperlipidemia, hypertension and coronary heart disease. Lancet 1995; 345: 362–364.

    Article  CAS  Google Scholar 

  17. Wierzbicki AS . Lipid lowering: another method of reducing blood pressure? J Hum Hypertens 2002; 16: 753–760.

    Article  CAS  Google Scholar 

  18. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281–1286.

    Article  CAS  Google Scholar 

  19. Poulter N, Sever PS . Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110(Suppl III): III-402 (abstract 1905).

  20. Wierzbicki AS . Statins and hypertension. J Hum Hypertens 2006; 20: 554–556.

    Article  CAS  Google Scholar 

  21. Nawarskas JJ, Spinler SA . Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998; 18: 1041–1052.

    CAS  Google Scholar 

  22. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439–444.

    Article  CAS  Google Scholar 

  23. Degli Esposti E, Berto P, Buda S, Di Nardo AM, Sturani A . The Pandora project: results of the pilot study. Am J Hypertens 1999; 12: 790–796.

    Article  CAS  Google Scholar 

  24. Guidelines for ATC classification and DDD assignment, 5th edn, WHO Collaborating Centre for Drug Statistics Methodology: Oslo, 2002.

  25. Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005; 61: 225–230.

    Article  Google Scholar 

  26. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM . Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021–1023.

    Article  Google Scholar 

  27. Camisasca P, Avanzini F, Alli C, Colombo F, Tognoni G . Overall cardiovascular risk still ignored in general practice care of hypertension. J Cardiovasc Risk 2002; 9: 147–152.

    Article  Google Scholar 

  28. Tragni E, Catapano AL, Bertelli A, Poli A . Achievement of the therapeutic goals for dyslipidemia in clinical practice: results of a survey among general practice physicians from Lombardy. Ital Heart J 2003; 4(Suppl 7): 47S–57S.

    PubMed  Google Scholar 

Download references

Acknowledgements

This study and its ongoing development are supported by a grant from Pfizer Italia SpA and we are also grateful for its assistance. We would sincerely thank Silvia Bustacchini for the invaluable contribution to management and analysis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Di Martino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Martino, M., Esposti, L., Filigheddu, F. et al. Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice. J Hum Hypertens 21, 53–59 (2007). https://doi.org/10.1038/sj.jhh.1002102

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002102

Keywords

This article is cited by

Search

Quick links